IgG receptor FcRn large subunit p51, FcRn, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor, Fcgrt, Fcrn.
FCGRT Human Recombinant is a glycosylated, polypeptide chain conteining 2 fragments: FCGRT (24-297aa) having a total 280 a.a and a a molecular weigh of 31.1kDa & B2M (21-119 aa) having a total 99 a.a and a a molecular weigh of 11.7kDa.
FCGRT is fused to a 6 a.a his-Tag at C-terminus and is purified by proprietary chromatographic techniques.
Sterile Filtered colorless solution.
The FCGRT solution (0.25mg/ml) contains 10% Glycerol and Phosphate-Buffered Saline (pH 7.4).
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.
Greater than 95.0% as determined by SDS-PAGE.
Measured by its binding ability in a functional ELISA with Human IgG1 Fc.
Amino acid sequence
AESHLSLLYH LTAVSSPAPG TPAFWVSGWL GPQQYLSYNS LRGEAEPCGA WVWENQVSWY WEKETTDLRI KEKLFLEAFK ALGGKGPYTL QGLLGCELGP DNTSVPTAKF ALNGEEFMNF DLKQGTWGGD WPEALAISQR WQQQDKAANK ELTFLLFSCP HRLREHLERG RGNLEWKEPP SMRLKARPSS PGFSVLTCSA FSFYPPELQL RFLRNGLAAG TGQGDFGPNS DGSFHASSSL TVKSGDEHHY CCIVQHAGLA QPLRVELESP AKSSHHHHHH.
IQRTPKIQVY SRHPAENGKS NFLNCYVSGF HPSDIEVDLL KNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDM.
Safety Data Sheet
The neonatal Fc receptor (FCGRT), a crucial player in the transport of immunoglobulins across various biological barriers, has emerged as a focal point in immunology and therapeutic protein delivery. In its human recombinant form, FCGRT provides a controlled system for investigating its structural intricacies, immunoglobulin binding properties, and potential applications in targeted drug delivery. This research embarks on an exploratory journey to unravel the diverse roles of FCGRT Human Recombinant, shedding light on its structural attributes, molecular interactions, and its promising avenues in improving the pharmacokinetics of therapeutic antibodies. By delving into the properties of FCGRT, scientists aim to enhance our understanding of immunoglobulin transport and pave the way for innovative strategies in drug development and delivery.
Structural Insights into FCGRT Human Recombinant:
FCGRT, a heterodimer consisting of alpha and beta subunits, possesses a unique structural configuration crucial for its interactions with immunoglobulins. The human recombinant form allows for a controlled exploration of the three-dimensional intricacies of FCGRT, providing insights into its binding affinities and conformational dynamics. Understanding its structure is fundamental for deciphering how FCGRT mediates the transport of immunoglobulins across biological barriers.
Immunoglobulin Transport Across Biological Barriers:
The primary function of FCGRT lies in its ability to transport immunoglobulins, especially IgG, across epithelial and endothelial barriers. This transport pathway, known as the neonatal Fc receptor-mediated transcytosis, ensures the passive transfer of maternal antibodies to newborns and plays a vital role in immune protection during the early stages of life. Studies involving FCGRT Human Recombinant illuminate the molecular mechanisms governing this transport process.
Applications in Drug Delivery and Therapy:
The unique ability of FCGRT to transport immunoglobulins has spurred investigations into its potential applications in drug delivery. FCGRT Human Recombinant is being explored as a tool to improve the pharmacokinetics of therapeutic antibodies, enhancing their stability and extending their half-life in circulation. This holds significant implications for the development of antibody-based therapies for a range of diseases, including autoimmune disorders and cancer.
Modulation of Immune Responses:
Beyond its role in immunoglobulin transport, FCGRT is implicated in the modulation of immune responses. FCGRT Human Recombinant studies have unveiled its interactions with immune cells and its potential influence on the activation and regulation of the immune system. This dual role positions FCGRT as a key player not only in passive immunity but also in the dynamic orchestration of immune responses.
Challenges and Future Directions:
While the potential of FCGRT Human Recombinant in drug delivery is promising, challenges persist. Fine-tuning its applications, understanding its interactions with diverse antibodies, and optimizing strategies for therapeutic use are critical considerations for translational success. Additionally, deciphering the intricate balance between immunoglobulin transport and immune modulation is an active area of investigation.
FCGRT Human Recombinant emerges as a sentinel in the realm of immunoglobulin transport and drug delivery, offering a controlled platform for scientific exploration. Its structural insights, immunoglobulin transport functions, and therapeutic applications position it as a key player in the evolving landscape of biopharmaceuticals. As researchers continue to delve into the molecular intricacies of FCGRT, they not only enhance our understanding of immunoglobulin transport but also pave the way for transformative advancements in drug delivery and antibody-based therapies, shaping the future of precision medicine and targeted therapeutics.